Liquidia is a healthcare company focused on developing and commercializing innovative therapies for patients with pulmonary diseases. Its core products include drug delivery systems and formulations, particularly for the treatment of pulmonary arterial hypertension. The company operates primarily in the biopharmaceutical segment, generating revenue through product sales and partnerships.
The investment profile of Liquidia may appeal more to value investors due to its current pricing relative to earnings and growth potential. However, the high risk associated with its operations and market volatility suggests a cautious approach. The stock may not provide immediate dividends, making it less suitable for income-focused investors.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-11-12 | Hold | Buy | Strong recent performance and positive revenue growth. |
| 2026-11-04 | Buy | Hold | Strong revenue growth but high volatility and risk. |
| 2026-10-25 | Hold | Buy | Strong recent performance, but high volatility persists. |
| 2026-10-19 | Sell | Hold | High volatility and uncertain fundamentals warrant caution. |
| 2026-10-02 | — | Sell | High risk with significant negative momentum and weak fundamentals. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-11-11 | Raymond James | Update | — → 77 | 53.425 |
| 2026-11-11 | Wells Fargo | Target Raised | — → 54 | 51.4 |
| 2026-11-11 | Wells Fargo | Target Raised | — → 40 | 51.4 |
| 2026-11-10 | BTIG | Target Raised | — → 87 | 51.4 |
| 2026-11-10 | Jefferies | Target Raised | — → 62 | 51.4 |
| 2026-10-15 | RBC Capital | Target Raised | — → 65 | 33.94 |
| 2026-10-15 | H.C. Wainwright | Target Raised | 58 → 65 | 33.94 |
| 2026-10-14 | Needham | Target Lowered | 72 → 58 | 26.81 |
| 2026-10-14 | Wells Fargo | Target Raised | 30 → 33 | 26.81 |
| 2026-10-14 | BTIG | Update | — → 70 | 26.81 |
| 2026-10-02 | Wedbush | Target Lowered | — → 58 | 27.99 |
| 2026-10-02 | H.C. Wainwright | Target Lowered | 130 → 58 | 27.99 |
| 2026-10-02 | Wells Fargo | Rating Downgraded | — → 30 | 27.99 |
| 2026-10-01 | Raymond James | Update | — → 53 | 30.26 |
| 2026-08-13 | Raymond James | Target Raised | 68 → 106 | 78.45 |
| 2026-08-13 | Wells Fargo | Target Raised | 62 → 108 | 78.79 |
| 2026-07-24 | H.C. Wainwright | Target Raised | — → 36 | 89.03 |
| 2026-07-24 | Piper Sandler | Target Raised | — → 129 | 89.03 |
| 2026-07-24 | RBC Capital | Target Raised | — → 130 | 89.03 |
| 2026-07-24 | Stephens | Target Raised | — → 130 | 89.03 |
| 2026-07-23 | H.C. Wainwright | Target Raised | 75 → 130 | 89.1132 |
| 2026-06-22 | BTIG | Target Raised | 59 → 109 | 71.07 |
| 2026-06-05 | H.C. Wainwright | Target Raised | 67 → 75 | 62.54 |
